Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06184035

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer (Tumorad)

Ph I/IIa Escalation/Expansion FIH, Open, Multi Center, Single Arm Study Evaluating Safety, Dosimetry and Early Efficacy of 177Lu-SN201 in Progressive/Treatment-refractory, Locally Advanced, Unresectable Metastatic or Recurrent Solid Tumors

Sponsor: Spago Nanomedical AB

Conditions Locally Advanced Solid Tumor Metastatic Cancer Recurrent Solid Tumor Refractory Cancer Solid Tumor Unresectable Solid Tumor

Interventions [177Lu]Lu-SN201

Updated 4 times since 2024 Last updated: Nov 17, 2025 Started: Dec 6, 2023 Primary completion: Dec 1, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Locally Advanced Solid Tumor and Metastatic Cancer and is currently actively recruiting participants. Spago Nanomedical AB leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Spago Nanomedical AB

Data source: Spago Nanomedical AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia
• Melbourne, Australia